BETHESDA, Md., Sept. 16, 2015 /PRNewswire/ -- Northwest
Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S.
biotechnology company developing DCVax® personalized immune
therapies for solid tumor cancers, today announced that Chief
Technical Officer, Dr. Marnix Bosch,
will present a new DCVax-Direct poster at the Inaugural
International Cancer Immunotherapy Conference: Translating Science
into Survival 2015. The Conference is being held at the
Sheraton New York Times Square Hotel from September 16th to 19th,
2015.
This first of its kind conference is a collaboration of four
prestigious cancer organizations on both sides of the Atlantic,
demonstrating the ever increasing attention towards immunotherapy.
They include the American Association of Cancer Research
(AACR), the European Association for Cancer Immunotherapy (CIMT),
the Cancer Research Institute (CRI), and the European Academy of
Tumor Immunology (EATI).
Dr. Bosch will discuss new and emerging information from the
Phase I trial of DCVax-Direct in regard to ongoing patient survival
and factors associated with such survival. The poster is
entitled "Cytokine Production by Human Dendritic Cells When
Administered Intratumorally Correlates with Clinical Outcome in
Subjects with Advanced Cancers." This poster presentation
will be presented in the 6:45 to 8:45 pm
(EDT) Session A on Wednesday,
September 16, 2015.
In addition to Dr. Bosch, other authors on the poster
presentation include Dr. Vivek
Subbiah and colleagues from MD Anderson Hospital and from UT
Health in Houston, as well as
several representatives from Cognate Bioservices.
The Poster and the accompanying presentation will be posted on
the NW Bio website following the presentation at
nwbio.com/webcast. There will be no live webcast of the
presentation.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on
developing personalized immunotherapy products designed to treat
cancers more effectively than current treatments, without
toxicities of the kind associated with chemotherapies, and on a
cost-effective basis, in both the United
States and Europe. The Company has a broad platform
technology for DCVax dendritic cell-based vaccines. The
Company's lead program is a 348-patient Phase III trial in newly
diagnosed Glioblastoma multiforme (GBM). GBM is the most
aggressive and lethal form of brain cancer, and is an "orphan
disease." The Company is under way with a 60-patient Phase
I/II trial with DCVax-Direct for all types of inoperable solid
tumors cancers. It has completed enrollment in the Phase I
portion of the trial. The Company previously conducted a
Phase I/II trial with DCVax-L for metastatic ovarian cancer
together with the University of
Pennsylvania. The Company previously received
clearance from the FDA for a 612-patient Phase III trial in
prostate cancer. In Germany,
the Company has received approval of a 5-year Hospital Exemption
for the treatment of all gliomas (primary brain cancers) outside
the clinical trial.
Disclaimer
Statements made in this news release that are not historical
facts, including statements concerning future treatment of patients
using DCVax and future clinical trials, are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as "expect," "believe,"
"intend," "design," "plan," "continue," "may," "will,"
"anticipate," and similar expressions are intended to identify
forward-looking statements. Actual results may differ
materially from those projected in any forward-looking
statement. Specifically, there are a number of important
factors that could cause actual results to differ materially from
those anticipated, such as risks related to the Company's ongoing
ability to raise additional capital, risks related to the Company's
ability to enroll patients in its clinical trials and complete the
trials on a timely basis, uncertainties about the clinical trials
process, uncertainties about the timely performance of third
parties, risks related to whether the Company's products will
demonstrate safety and efficacy, risks related to the Company's and
Cognate's abilities to carry out the intended manufacturing
expansions contemplated in the Cognate Agreements, risks related to
the Company's ability to carry out the Hospital Exemption program
and risks related to possible reimbursement and pricing.
Additional information on these and other factors, including Risk
Factors, which could affect the Company's results, is included in
its Securities and Exchange Commission ("SEC") filings.
Finally, there may be other factors not mentioned above or included
in the Company's SEC filings that may cause actual results to
differ materially from those projected in any forward-looking
statement. You should not place undue reliance on any
forward-looking statements. The Company assumes no obligation
to update any forward-looking statements as a result of new
information, future events or developments, except as required by
securities laws.
Logo -
http://photos.prnewswire.com/prnh/20110329/SF73084LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nw-bio-presenting-new-dcvax-direct-poster-at-the-inaugural-international-cancer-immunotherapy-conference-translating-science-into-survival-in-new-york-city-on-wednesday-september-16-2015-300144066.html
SOURCE Northwest Biotherapeutics